Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction

Journal of Clinical Oncology

Volumn 28, Issue 25, 2010, Pages 3901-3904

  Ewer, Michael S ^a   Ewer, Steven M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; TRASTUZUMAB; TROPONIN; TROPONIN I; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DAMAGE; CELL SURVIVAL; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; GENE EXPRESSION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HUMAN; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; RISK FACTOR; TREATMENT DURATION; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; FEMALE; METABOLISM; NOTE; TIME;

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; DRUG INTERACTIONS; FEMALE; HEART DISEASES; HUMANS; TIME FACTORS; TROPONIN I;

EID: 77957576145     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.6274     Document Type: Editorial

References (16)

1. Cardinale D, Colombo A, Torrisi R, et al: Trastuzumab-induced cardiotoxicity: Clinical and prognostic implication of troponin I elevation. J Clin Oncol 28:3910-3916, 2010
2. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979 (Pubitemid 10218041)
3. Billingham ME, Mason JW, Bristow MR, et al: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatment Rep 62:865-72, 1978 (Pubitemid 8377880)
4. Ewer M, Benjamin R: Formulae for predicting the likelihood of developing congestive heart failure following anthracycline chemotherapy: Added evidence for early cardiotoxicity. J Card Fail 11:S159, 2005 (abstr 259)
5. Cardinale D, Sandri MT, Martinoni A, et al: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13:710-715, 2002 (Pubitemid 34567376)
6. Ewer MS, Lippman SM: Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 23:2900-2902, 2005 (Pubitemid 46224107)
7. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant Trial. J Clin Oncol 25:3859-3865, 2007 (Pubitemid 47477261)
8. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005 (Pubitemid 46657378)
9. Slamon D, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009
10. Joensuu H, Bono P, Kataja V, et al: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 27:5685-5692, 2009
11. Ewer SM, Ewer MS: Anthracycline cardiotoxicity: Why are we still interested? Oncology (Williston Park) 23:234-235, 239, 2009
12. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
13. Zhao YY, Sawyer DR, Baliga RR, et al: Neuregulins promote survival and growth of cardiac myocytes: Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273:10261-10269, 1998 (Pubitemid 28227629)
14. de Korte MA, de Vries EG, Lub-de Hooge MN, et al: 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 43:2046-2051, 2007 (Pubitemid 47380360)
15. Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233, 2007 (Pubitemid 46121873)
16. Gianni L, Eiermann W, Semiglazov V, et al: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384, 2010